Melanoma Biomarker Study
Completed
Conditions studied: Metastatic Melanoma
In brief
The purpose of this study is to measure the level of a specific protein, CXCL1, in the blood of patients with untreated, metastatic (Stage IV) melanoma. These levels will be compared to blood levels in normal controls. If the levels are elevated in metastatic melanoma, further studies to determine if this correlates with presence and extent of disease will be pursued.
Key facts
- Study ID
- NCT00348088
- Run by
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
- People needed
- 20
- Starts
- 2006-05-01
- Expected to finish
- 2011-09-01
- Last updated by the study team
- 2012-12-13
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: accepted.
You may qualify if…
- Histologic diagnosis of melanoma; primary may be cutaneous, mucosal or ocular.
- Evidence of metastatic disease based on standard AJCC staging.
- Willing to give written informed consent.
- Willing and able to comply with protocol procedures.
- At least 18 years of age.
- No prior chemotherapy, immunotherapy, or radiotherapy.
- Are able to safely donate 50 mL of blood.
- Have a central venous catheter in place (this will not be placed for participation in this trial)
You may not qualify if…
- Known diagnosis of a chronic inflammatory disease, ie: Rheumatoid Arthritis, Systemic Sclerosis, Inflammatory bowel disease
- Known diagnosis of NYHA class 3 or 4 Congestive Heart Failure
- Are unable to safely donate 50 mL blood
- Known HIV, Hepatitis B, or Hepatitis C infection.
- Any malignancy within 5 years, other than melanoma (for patients); Have any malignancy within the past 5 years including melanoma (for normal controls). Basal cell and squamous cell skin cancers are permitted in all participants.
Where it is running
- Johns Hopkins University - Sidney Kimmel Comprehensive Cancer Center — Baltimore, Maryland, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.